NO20076431L - Pyridazinderivater - Google Patents

Pyridazinderivater

Info

Publication number
NO20076431L
NO20076431L NO20076431A NO20076431A NO20076431L NO 20076431 L NO20076431 L NO 20076431L NO 20076431 A NO20076431 A NO 20076431A NO 20076431 A NO20076431 A NO 20076431A NO 20076431 L NO20076431 L NO 20076431L
Authority
NO
Norway
Prior art keywords
pyridazine derivative
pyridazine
derivative
rhar
esters
Prior art date
Application number
NO20076431A
Other languages
English (en)
Inventor
Werner Neidhart
Bernd Kuhn
Alexander Mayweg
Kurt Amrein
Daniel Hunziker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076431(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20076431L publication Critical patent/NO20076431L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel og farmasøytisk akseptable salter og estere derav, hvor Rtil Rhar betydningen gitt i krav 1. De kan bli anvendt for å danne farmasytiske preparater.
NO20076431A 2005-07-05 2007-12-14 Pyridazinderivater NO20076431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106098 2005-07-05
PCT/EP2006/063533 WO2007003521A2 (en) 2005-07-05 2006-06-26 Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

Publications (1)

Publication Number Publication Date
NO20076431L true NO20076431L (no) 2008-04-01

Family

ID=36781523

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076431A NO20076431L (no) 2005-07-05 2007-12-14 Pyridazinderivater

Country Status (32)

Country Link
US (1) US7678795B2 (no)
EP (1) EP1904455B1 (no)
JP (1) JP4787321B2 (no)
KR (1) KR100979582B1 (no)
CN (1) CN101528713B (no)
AR (1) AR054814A1 (no)
AT (1) ATE520670T1 (no)
AU (1) AU2006265201C1 (no)
BR (1) BRPI0613565A2 (no)
CA (1) CA2612740C (no)
CL (1) CL2009001936A1 (no)
CR (1) CR9587A (no)
CY (1) CY1112401T1 (no)
DK (1) DK1904455T3 (no)
EC (1) ECSP088082A (no)
ES (1) ES2370039T3 (no)
HR (1) HRP20110808T1 (no)
IL (1) IL188182A (no)
MA (1) MA29909B1 (no)
MX (1) MX2007016352A (no)
MY (1) MY144209A (no)
NO (1) NO20076431L (no)
NZ (1) NZ564260A (no)
PL (1) PL1904455T3 (no)
PT (1) PT1904455E (no)
RS (1) RS51994B (no)
RU (1) RU2401832C2 (no)
SI (1) SI1904455T1 (no)
TW (1) TWI323258B (no)
UA (1) UA94052C2 (no)
WO (1) WO2007003521A2 (no)
ZA (1) ZA200710972B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
US8236789B2 (en) 2008-08-29 2012-08-07 Kowa Company, Ltd. 1-adamantyl azetidin-2-one derivatives and drugs containing same
EP2348019A4 (en) 2008-10-29 2012-10-31 Kowa Co 1,2-DIAZETIDIN-3-ON DERIVATIVE AND PHARMACEUTICAL ACTIVE INGREDIENTS
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
DK2707101T3 (da) * 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105705492B (zh) * 2013-11-05 2019-11-05 豪夫迈·罗氏有限公司 作为rorc调节剂用于治疗自身免疫性疾病的5,6,7,8-四氢-5,8-亚甲基噌啉衍生物
EP3292108A1 (en) * 2015-05-04 2018-03-14 H. Hoffnabb-La Roche Ag PYRIDAZINE DERIVATIVES AS RORc MODULATORS
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CA3042317A1 (en) * 2016-11-01 2018-05-11 F.Hoffmann-La Roche Ag Pyridazine derivatives as rorc modulators
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
KR102780960B1 (ko) * 2021-10-19 2025-03-12 조선대학교산학협력단 대사성 질환의 예방 또는 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
DE602004025220D1 (de) * 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen

Also Published As

Publication number Publication date
US7678795B2 (en) 2010-03-16
MX2007016352A (es) 2008-03-05
DK1904455T3 (da) 2011-09-12
ZA200710972B (en) 2008-10-29
PT1904455E (pt) 2011-10-04
NZ564260A (en) 2010-12-24
EP1904455A2 (en) 2008-04-02
KR20080019272A (ko) 2008-03-03
JP4787321B2 (ja) 2011-10-05
CN101528713A (zh) 2009-09-09
CN101528713B (zh) 2013-05-22
TW200738241A (en) 2007-10-16
TWI323258B (en) 2010-04-11
IL188182A0 (en) 2008-03-20
HK1134087A1 (en) 2010-04-16
AU2006265201A1 (en) 2007-01-11
ES2370039T3 (es) 2011-12-12
IL188182A (en) 2011-10-31
MA29909B1 (fr) 2008-11-03
CY1112401T1 (el) 2015-12-09
MY144209A (en) 2011-08-15
KR100979582B1 (ko) 2010-09-01
ATE520670T1 (de) 2011-09-15
AR054814A1 (es) 2007-07-18
PL1904455T3 (pl) 2012-01-31
AU2006265201B2 (en) 2010-07-15
BRPI0613565A2 (pt) 2011-01-18
RS51994B (sr) 2012-04-30
RU2401832C2 (ru) 2010-10-20
AU2006265201C1 (en) 2010-12-09
RU2008103483A (ru) 2009-08-10
JP2009500370A (ja) 2009-01-08
CL2009001936A1 (es) 2010-02-19
WO2007003521A3 (en) 2009-02-05
UA94052C2 (uk) 2011-04-11
WO2007003521A2 (en) 2007-01-11
EP1904455B1 (en) 2011-08-17
CA2612740C (en) 2011-07-26
SI1904455T1 (sl) 2011-11-30
CA2612740A1 (en) 2007-01-11
HRP20110808T1 (hr) 2011-12-31
ECSP088082A (es) 2008-02-20
CR9587A (es) 2008-01-25
US20070010519A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
NO20076431L (no) Pyridazinderivater
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
MX2010005824A (es) Derivados de aminotiazol.
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20080554L (no) Pyrazolonderivater
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
WO2005051906A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2009115517A3 (en) Pyridines and pyrazines as inhibitors of pi3k
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
NO20070445L (no) Pyrimidinderivater.
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
MX2010005714A (es) Compuestos de piridina.
GB0314967D0 (en) Piperazine derivatives
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
MX2012001229A (es) Derivados de piperidin y su uso para el tratamiento de la obesidad, diabetes y aterosclerosis.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application